ICCR乳腺浸润癌新辅助治疗后结构化报告数据集
国际癌症报告合作组织(ICCR)召集乳腺病理专家及外科和肿瘤科代表,基于当前证据和国际公开咨询反馈,制定了新辅助治疗后乳腺标本结构化报告数据集。该数据集纳入新辅助治疗特异的数据要素(核心或非核心),提出标本处理与报告实用方法,强调肿瘤反应和残留病变的标准化报告对后续治疗决策至关重要。
要点
- 新辅助治疗后乳腺标本应使用专用结构化数据集报告肿瘤反应与残留病变。
- 数据集含新辅助特异数据要素,分核心与非核心,需与浸润癌及淋巴结数据集联用。
- 标准化报告肿瘤反应和残留病变是后续治疗决策的关键。
核心结论
- 新辅助治疗后肿瘤反应和残留病变的高质量标准化报告对每位患者的后续治疗决策至关重要。
研究设计与样本
- ICCR召集乳腺病理专家小组(含一名外科和一名肿瘤科代表)批判性审查和讨论当前证据。
- 国际公开咨询的反馈对该数据集的制定至关重要。
主要发现
- 专家小组认为需要专用数据集报告新辅助治疗后乳腺标本,纳入新辅助特异的核心理或非核心数据要素。
- 该数据集提出新辅助治疗后乳腺切除标本处理和报告的实用方法。
- 每个数据要素的注释阐明术语、讨论现有证据并突出证据有限需进一步研究的领域。
- 该数据集与浸润性乳腺癌及乳腺肿瘤手术切除淋巴结数据集重叠,应酌情联用。
关键数值与推荐
- 数据要素分为核心或非核心。
- 完整数据集可在ICCR网站免费获取。
临床怎么用
- 病理科医生报告新辅助治疗后乳腺标本时应使用该专用数据集,并酌情与浸润癌和淋巴结数据集联用。
- 报告应聚焦肿瘤反应和残留病变的标准化描述,以支持后续管理决策。
局限性
- 文中指出部分领域证据有限,需进一步研究。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
AIMS: The International Collaboration on Cancer Reporting (ICCR), a global alliance of major (inter-)national pathology and cancer organisations, is an initiative aimed at providing a unified international approach to reporting cancer. ICCR recently published new data sets for the reporting of invasive breast carcinoma, surgically removed lymph nodes for breast tumours and ductal carcinoma in situ, variants of lobular carcinoma in situ and low-grade lesions. The data set in this paper addresses the neoadjuvant setting. The aim is to promote high-quality, standardised reporting of tumour response and residual disease after neoadjuvant treatment that can be used for subsequent management decisions for each patient. METHODS: The ICCR convened expert panels of breast pathologists with a representative surgeon and oncologist to critically review and discuss current evidence. Feedback from the international public consultation was critical in the development of this data set. RESULTS: The expert panel concluded that a dedicated data set was required for reporting of breast specimens post-neoadjuvant therapy with inclusion of data elements specific to the neoadjuvant setting as core or non-core elements. This data set proposes a practical approach for handling and reporting breast resection specimens following neoadjuvant therapy. The comments for each data element clarify terminology, discuss available evidence and highlight areas with limited evidence that need further study. This data set overlaps with, and should be used in conjunction with, the data sets for the reporting of invasive breast carcinoma and surgically removed lymph nodes from patients with breast tumours, as appropriate. Key issues specific to the neoadjuvant setting are included in this paper. The entire data set is freely available on the ICCR website. CONCLUSIONS: High-quality, standardised reporting of tumour response and residual disease after neoadjuvant treatment are critical for subsequent management decisions for each patient.
引用
- Bossuyt V, Provenzano E, Symmans WF, et al. A dedicated structured data set for reporting of invasive carcinoma of the breast in the setting of neoadjuvant therapy: recommendations from the International Collaboration on Cancer Reporting (ICCR). Histopathology. 2024. PMID: 38443320. doi:10.1111/his.15165
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。